



## SCALE UP HIV TREATMENT FOR CHILDREN: THE RIGHT TOOLS, RIGHT NOW!

*Practical &  
Programmatic Perspectives*



*Eleen struggles to give her child foul-tasting  
paediatric antiretrovirals in Cape Town, South Africa.  
© Mariella Furrer/DNDi*

Thursday 21 July 2016, 18:30-20:30  
AIDS 2016, Session Room 5  
*Dinner and refreshments will be served*

Despite major efforts to increase the number of children on HIV treatment and a continuing reduction in mother-to-child transmission of HIV, treatment coverage for children remains unacceptably low. Suboptimal paediatric antiretroviral formulations contribute heavily to this treatment gap.

This AIDS 2016 satellite session will explore the steps necessary to introduce new, optimal paediatric formulations. An overview of the process from drug development to patient administration will be presented, highlighting practical implementation steps that programmes may consider to accelerate the introduction and scale up of new paediatric ARV formulations. Panellists will also share programmatic experiences from early implementation of an improved formulation of the World Health Organization (WHO)-recommended combination for children under three years of age: lopinavir/ritonavir oral pellets.

### AGENDA

#### Welcome and Introduction

Polly Clayden, HIV i-Base, Chair & Moderator

#### Keynote Remarks

Dr Anban Pillay, Executive Director, Department of Health South Africa

#### Panel I: What does it take to select, prioritise, and develop optimal ARV formulations for children

*Panelists:* Dr Shaffiq Essajee, HIV Department, PMTCT and Maternal Child Health, WHO; Carmen Perez, Casas Technical Manager, UNITAID; Denis Broun, Global Director of Access, Cipla; Dr Marc Lallemand, Head of Paediatric HIV Programme, Drugs for Neglected Diseases initiative

#### Panel II: How to ensure access to new paediatric formulations within country programmes

*Panelists:* Nandita Sugandhi, Senior Clinical Officer at Clinton Health Access Initiative; Dr Moherndran Archary, Paediatric Infectious Disease Specialist, King Edward VIII Hospital, Durban; Nelson Juma Otwoma, National Coordinator, NEPHAK

#### Panel III: What does it take to introduce new formulations and implement programmes

*Panelists:* Professor Elizabeth Maleche Obimbo, Principle Investigator, LIVING study; Victor Musiime, Senior Lecturer at Makerere University, College of Health Sciences, Department of Paediatrics and Child Health, Kampala, Uganda